Merck has received an assessment from the Data Monitoring Committee (DMC) for its Phase II/III EPOCH study of MK-8931 in patients with mild to moderate Alzheimer’s disease. The DMC has completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol. The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least thre...